171 related articles for article (PubMed ID: 26135026)
1. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
Pho MT; Jensen DM; Meltzer DO; Kim AY; Linas BP
J Viral Hepat; 2015 Aug; 22(8):630-8. PubMed ID: 26135026
[TBL] [Abstract][Full Text] [Related]
2. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
4. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.
Kuehne FC; Bethe U; Freedberg K; Goldie SJ
Arch Intern Med; 2002 Dec 9-23; 162(22):2545-56. PubMed ID: 12456226
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
[TBL] [Abstract][Full Text] [Related]
8. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
10. [Retreatment options for patients with chronic hepatitis C].
Hrstić I; Ostojić R; Vucelić B
Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
[TBL] [Abstract][Full Text] [Related]
11. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
[TBL] [Abstract][Full Text] [Related]
13. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.
Wright M; Grieve R; Roberts J; Main J; Thomas HC;
Health Technol Assess; 2006 Jul; 10(21):1-113, iii. PubMed ID: 16750059
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
17. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
Akhan SC; Gurel E; Sayan M
Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Obach D; Deuffic-Burban S; Esmat G; Anwar WA; Dewedar S; Canva V; Cousien A; Doss W; Mostafa A; Pol S; Buti M; Siebert U; Fontanet A; Mohamed MK; Yazdanpanah Y
Clin Infect Dis; 2014 Apr; 58(8):1064-71. PubMed ID: 24510934
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
20. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
